CDK9 and esophageal adenocarcinoma: In both experiments, xenograft tumor growth was significantly inhibited by the CDK9 inhibitors compared to control from day 3 (Flavopiridol) and day 6 (CAN508) to the end of experiment indicating efficacy of both inhibitors in controlling tumor growth in esophageal adenocarcinoma xenografts.